Skip to content

Effects of Urban Nature on Stress and Quality of Life

Effects of Urban Nature on Stress and Quality of Life of Subjects With Elevated Stress Levels - a Three-armed Randomized Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04780646
Enrollment
93
Registered
2021-03-03
Start date
2022-06-29
Completion date
2024-12-15
Last updated
2023-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress, Psychological

Keywords

Nature therapy, Stress

Brief summary

The aim of this study is to investigate the effects of regular nature therapy in urban nature with guidance of a licensed nature therapist on stress, quality of life and physical symptoms of subjects with elevated stress levels.

Interventions

BEHAVIORALNature therapy in urban nature

Nature therapy means visits in nature, actively perceiving the flora and fauna

BEHAVIORALCity Walk

City Walk means walking through urban surroundings (houses, streets, concrete..) with as little as possible contact to nature

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* stress with at least 4 of 10 points on the Numeric Analogue Scale (NAS) at least 1 month * at least 3 of the following 8 stress-associated symptoms: sleep disturbances, inappetence or increased appetite, shoulder neck tension/back pain, tension headache, concentration disturbances, exhaustion, nervousness/irritability, stress-associated digestive complaints.

Exclusion criteria

* serious acute or chronic diseases * pregnancy or lactation * known serious mental illness * immobility or restriction for gymnastics exercises due to orthopaedic, neurological or other medical cause * participation in another study

Design outcomes

Primary

MeasureTime frameDescription
Stress questionnaire (Cohen Perceived Stress Scale, CPSS)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksChange from Baseline in the CPSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress.

Secondary

MeasureTime frameDescription
Zerssen symptom list (B-LR and B-LR')Date of Inclusion (Baseline), after 8 weeks and after 16 weeksAssessing full scale, range 20-80, higher score meaning a better outcome
International Physical Activity Questionnaire (IPAQ)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksMET minutes represent the amount of energy expended carrying out physical activity. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS; higher score meaning better outcome; range 0 to around 3000 MET minutes a week
Maslach Burnout Inventory (MBI)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksAssessing full scale, range 0-96, higher score meaning a better outcome
Mindfulness (Freiburger Fragebogen zur Achtsamkeit, FFA)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksAssessing full scale, range 0-56, higher score meaning a better outcome
General Self-Efficacy Short Scale-3 (GSE-3)Date of Inclusion (Baseline), after 8 weeks and after 16 weeks
Perceived Benefits of Nature Questionnaire (PBNQ)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksmean score of the 11 items, range 1-7, lower score meaning a better outcome
Subjective Vitality Scale (SVS-G state)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksAssessing full scale, range from 0-28, lower score meaning a better outcome
Flourishing Scale (FS)Date of Inclusion (Baseline), after 8 weeks and after 16 weeksAssessing full scale, range 8-56, higher score meaning a better outcome
Hospital Anxiety and Depression Scale (HADS)Date of Inclusion (Baseline), after 8 weeks and after 16 weeks
Sociodemographic MeasurementsDate of Inclusion (Baseline)Age, gender, marital status, number of people in household, education level, employment status, job, personal net income, household income
Behavioural questions: doctor visits and healthDate of Inclusion (Baseline), after 8 weeks and after 16 weeksamount of doctor visits, amount of sick leave days in the last 2 months
Expectation questionsDate of Inclusion (Baseline)for intervention 1 and 2 on a 6-point likert scale from 1 (very strong) to 6 (nothing at all)
Behavioural questions: cigarette consumptionDate of Inclusion (Baseline), after 8 weeks and after 16 weeksNumber of cigarettes on average per day in the last month
Behavioural questions: alcohol consumptionDate of Inclusion (Baseline), after 8 weeks and after 16 weeksNumber of alcoholic beverages on average per week in the last month
Behavioural questions: time in natureDate of Inclusion (Baseline), after 8 weeks and after 16 weeksamount of hours spent in nature per week in the last month
Behavioural questions: nature as priorityDate of Inclusion (Baseline), after 8 weeks and after 16 weeksif spending time in nature is seen as a priority on a 6-point likert scale 1 (very strong) to 6 (nothing at all)
Heart Rate (HR)Date of inclusion (baseline), after 8 weeks, after 16 weeks24h measuring by faros 180
Heart Rate Variability (HRV)Date of inclusion (baseline), after 8 weeks, after 16 weeks24h measuring by faros 180
Profile of Mood States (POMS)Date of Inclusion (Baseline), after 8 weeks and after 16 weeks

Other

MeasureTime frameDescription
Qualitative interviews in individual interviews8 weeks after inclusionQualitative assessment will be carried out in 45-minute individual interviews in 20 (randomized selected) patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis.

Countries

Germany

Contacts

Primary ContactMiriam Rösner
m.roesner@immanuel.de00493080505682

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026